ALXN:NSD-Alexion Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 168.44

Change

+1.90 (+1.14)%

Market Cap

USD 36.79B

Volume

1.79M

Average Target Price

USD 162.81 (-3.34%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

Company Website : http://www.alexion.com

Address : 121 Seaport Boulevard, Boston, MA, United States, 02210

Employees : 3,837

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.27

52 Week High : 168.51

Short Ratio : 2.92

52 Week Low : 94.82

Shorted Shares : 7,835,359

200 Day Moving Average : 143.17

Shorted Shares Previous Month : 7,796,784

50 Day Moving Average : 153.85

Shares Held By Insiders : 3.9%

Short Percentage : 4.00%

Shares Held by Institutions : 91.16%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+12.72 (+8.11%)

 USD61.85B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

-0.40 (-0.18%)

 USD56.98B 21.40 15.53
REGN Regeneron Pharmaceuticals, Inc

+2.06 (+0.41%)

 USD54.04B 16.53 12.83
BNTX BioNTech SE

+5.62 (+3.60%)

 USD36.10B -99,999.99 N/A
BGNE BeiGene, Ltd

+9.25 (+3.16%)

 USD27.46B N/A N/A
SGEN Seagen Inc

+2.73 (+1.89%)

 USD26.25B 42.96 35.78
RPRX Royalty Pharma plc

+1.34 (+3.23%)

 USD25.16B 22.60 15.19
GMAB Genmab A/S

+0.82 (+2.29%)

 USD23.17B 26.59 3.31
CVAC CureVac N.V

+2.16 (+1.95%)

 USD21.12B N/A N/A
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A

ETFs Containing ALXN

Symbol Name Weight Mer Price(Change) Market Cap
BBH VanEck Vectors Biotech ET.. 0.00 % 0.35 %

+2.55 (+1.39%)

 USD0.50B
ZBIO ProShares UltraPro Short .. 0.00 % 0.95 %

N/A

 USD2.51M
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.12 (+2.12%)

 USD0.35B
ETLI:F L&G Pharma Breakthrou.. 0.00 % 0.49 %

+0.17 (+1.69%)

 USD0.03B
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.16 (+2.28%)

 USD0.03B
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.11 (+2.26%)

 USD0.34B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.15 (+2.27%)

 USD0.34B
CMUE-F:CA CIBC Multifactor U.S. Equ.. 0.00 % 0.25 %

N/A

 N/A
ZHU:CA BMO Equal Weight US Healt.. 0.00 % 0.35 %

+0.33 (+0.78%)

 USD0.04B
CMUE:CA CIBC Multifactor U.S. Equ.. 0.00 % 0.25 %

+0.19 (+0.76%)

 USD0.26B
ZUH:CA BMO Equal Weight US Healt.. 0.00 % 0.35 %

+1.12 (+1.46%)

 USD0.51B
XBI SPDR S&P Biotech ETF 0.00 % 0.35 %

+4.48 (+3.49%)

 USD7.85B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

+3.23 (+3.80%)

 USD0.20B
UBIO ProShares UltraPro Nasdaq.. 0.00 % 0.95 %

N/A

 USD0.02B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.58 %

+1.61 (+2.18%)

 USD0.28B
MNA IQ Merger Arbitrage ETF 0.00 % 0.77 %

+0.08 (+0.24%)

 USD0.72B
LABD Direxion Daily S&P Biotec.. 0.00 % 1.07 %

-2.53 (-10.14%)

 USD0.07B
IBB iShares Nasdaq Biotechnol.. 0.00 % 0.46 %

+2.99 (+1.97%)

 USD10.74B
FHH:CA FT AlphaDEX U.S. Health C.. 0.00 % 0.70 %

+0.23 (+0.59%)

 USD0.02B
CFO VictoryShares US 500 Enha.. 0.00 % 0.38 %

+0.80 (+1.15%)

 USD0.86B
CFA VictoryShares US 500 Vola.. 0.00 % 0.35 %

+0.76 (+1.09%)

 USD0.68B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

-0.86 (-3.91%)

 USD0.01B
ETLI:XETRA L&G Pharma Breakthrou.. 0.00 % 0.49 %

+0.17 (+1.63%)

 USD0.03B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.81% 62% D- 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.81% 62% D- 51% F
Trailing 12 Months  
Capital Gain 62.10% 64% D 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 62.10% 64% D 52% F
Trailing 5 Years  
Capital Gain 5.87% 57% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.87% 57% F 27% F
Average Annual (5 Year Horizon)  
Capital Gain 1.41% 36% F 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.41% 35% F 31% F
Risk Return Profile  
Volatility (Standard Deviation) 21.96% 94% A 72% C-
Risk Adjusted Return 6.40% 37% F 31% F
Market Capitalization 36.79B 99% A+ 97% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 61.23 16% F 20% F
Price/Book Ratio 3.10 67% D+ 50% F
Price / Cash Flow Ratio 12.25 7% F 34% F
EV/EBITDA 35.79 21% F 28% F
Management Effectiveness  
Return on Equity 5.26% 94% A 63% D
Return on Invested Capital 20.68% 92% A- 92% A-
Return on Assets 10.10% 97% A+ 95% A
Debt to Equity Ratio 20.77% 42% F 60% D-
Technical Ratios  
Short Ratio 2.92 55% F 39% F
Short Percent 3.72% 71% C- 47% F
Beta 1.27 57% F 43% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.